Exit Interview: Abernethy Tells Why She’s Leaving FDA – But Staying On Her Own Path
The FDA’s outgoing second-in-command, Amy Abernethy, is confident she’s leaving the agency in good hands but plans to continue to advocate for patients by focusing on areas such as trial design and use of real-world evidence. In this interview with Medtech Insight, Abernethy also talks about the work she put in to make sure there was a change in IT culture at the agency, among other topics.
You may also be interested in...
The US regulatory agency is looking for qualified independent contractors to help guide upgrades to its IT systems, make recommendations and report on how things are going.
Agency would get $300m, half going to modernizing its IT systems. It recently ran into disagreement with industry after using user fees to pay for some upgrades.
The US regulatory agency would get $300m, of which half would be to modernize its IT systems. Recently, it’s run into some disagreement with industry after using user fees to pay for some upgrades.